Drug Trial Radar · NCT03107611
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
654
Actual
Start
Feb 29, 2016
Primary completion
May 15, 2017
Study completion May 15, 2017
Sponsor
- Lead sponsor
- Mylan Inc.Industry
- Sponsor type
- Industry
- Collaborators
- DPT Laboratories, Ltd.
- First posted
- Apr 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis. To establish superiority of each active treatment over the placebo.
Conditions
- Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%Drug
Placebo CreamDrug
Pimecrolimus Cream, 1%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])Time frame: Day 15
- Proportion of Per Protocol Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])Time frame: Day 15
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
Research Facility 6
Boynton Beach, Florida
Research Facility 4
Coral Gables, Florida
Research Facility 5
Miami, Florida
Research Facility 10
Miami, Florida
Research Facility 1
Miami Lakes, Florida
Research Facility 9
Miramar, Florida
Research Facility 33
Sweetwater, Florida
Research Facility 23
Boise, Idaho
Research Facility 28
Overland Park, Kansas
Research Facility 32
Louisville, Kentucky
Research Facility 13
New Orleans, Louisiana
Research Facility 7
Saint Joseph, Missouri
Research Facility 19
Omaha, Nebraska
Research Facility 29
Albuquerque, New Mexico
Research Facility 24
Charlotte, North Carolina
Research Facility 2
High Point, North Carolina
Resarch Facility 8
Philadelphia, Pennsylvania
Research Facility 18
Johnston, Rhode Island
Research Facility 20
Austin, Texas
Research Facility 16
College Station, Texas
Research Facility 31
Pflugerville, Texas
Research Facility 17
Sugar Land, Texas
Research Facility 22
West Jordan, Utah
Research Facility 15
Richmond, Virginia
Research Facility 26
Spokane, Washington
Research Facility 11
Santo Domingo, Dominican Republic
Research Facility 12
San Pedro Sula, Honduras
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.